Auriga, Kreaxi, Alto in €2.4m round for Nosopharm

The three investors joined Nosopharm's pool of previous investors.

Auriga invested through the Auriga IV Bioseeds fund, closed on €40m in 2013, and which deploys €500,000-3m in startups operating in the fields of infectology and microbiology.

The funds raised will allow Nosopharm to accelerate the regulatory preclinical development of its first antibiotic molecule, NOSO-95179, which targets the enterobacteriaceae bacteria. The first-in-man studies for the molecule are expected to start in 2019.

Nosopharm said it would also submit new patent applications covering new therapeutic classes of anti-infectives by the end of 2018.

Kreaxi and Alto recently took part in a €3.5m round for x-ray imaging technology specialist MultiX, alongside Omnes Capital and other backers.

Previous funding
Nosopharm has raised a total of €4.2m in equity funding to date, in addition to €1.9m in grants from IMI, DGA, BPI France, Region Languedoc-Roussillon and Feder.

In 2013, Nosopharm received a first €870,000 seed round to start developing its technology.

Company
Founded in 2009 in Lyon and led by Philippe Villain-Guillot, Nosopharm is a biotechnology company specialised in the research and development of new antibacterial and antimicrobial molecules. The group claims to be addressing the issue of bacterial multi-drug resistance to antibiotics, which is particularly problematic with hospital-acquired infections.

Nosopharm mainly develops NOSO-95179 – an antibiotic for the treatment of multi-drug-resistant hospital-acquired infections. It currently employs seven people.

People
Kreaxi – Gwenaël Hamon (investment director).
Alto Invest – Benoit Thiedey (investment manager)
Auriga Partners – Franck Lescure (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• Venture
• France